RemeGen Co. Ltd. Class A (688331.SS / 09995.HK): The Dual-Engine Chinese Biopharma Engine

I. Introduction & Episode Roadmap

On a Monday morning in April 2026, a wire transfer of US$650 million arrived in the bank accounts of a company headquartered in 烟台 Yantai, a port city on the Shandong peninsula traditionally known for agriculture and shipping rather than molecular biology.¹ The payment came from AbbVie for the ex-Greater China rights to RC148, a drug candidate that had never been administered to a patient outside a clinical trial and held no approved indications worldwide.²

For 荣昌生物 RemeGen, that single payment exceeded the cumulative revenue generated by every product the company had sold in China across its commercial history through 2024. It transformed what would have been an ordinary first half of 2026 into a dramatic financial report: revenue reached RMB 5.85 billion, up 433% year over year, with net profit attributable to shareholders reaching RMB 4.66 billion.³

That figure is the single most important metric for understanding the company's mid-2026 financial condition — and also the most misleading. Excluding the AbbVie licensing income, RemeGen's underlying drug sales during the same six-month period totaled RMB 1.34 billion, representing 22.3% year-over-year growth.³ While steady, those organic product revenues represented only a small fraction of the headline figure.

This dynamic highlights the core tension within RemeGen. The company possesses a genuine scientific franchise consisting of two internally discovered, domestically manufactured biologics — both first-of-their-kind approvals in China and both commercialized across more than a thousand hospitals. Yet its business model has been unable to fund ongoing operations through product sales alone for six consecutive years. Instead, it has relied on a sequence of equity raises and out-licensing transactions, each arriving just as cash reserves neared exhaustion.

The two engines. Engine one is 泰爱 Telitacicept (RC18), a recombinant TACI-Fc fusion protein designed to simultaneously neutralize two immune-signaling proteins, BLyS and APRIL. Engine two is 爱地希 Disitamab Vedotin (RC48), a HER2-targeting antibody-drug conjugate that became China's first domestically discovered ADC to win marketing approval.⁴ Neither drug was a copy of a Western compound; both were invented in Yantai.

The paradox. RemeGen raised US$590 million in a Hong Kong initial public offering in November 2020, during the height of the global biotech bull market.⁵ It raised an additional RMB 2.61 billion on Shanghai's 科创板 STAR Market in March 2022.⁶ In August 2021, it executed what was then the largest out-licensing deal in Chinese biopharma history, securing US$200 million upfront and up to US$2.4 billion in potential milestones from Seagen for disitamab vedotin.⁷ Over the subsequent four years, the company expended nearly all of those funds, pushed its balance sheet near financial strain, watched Pfizer inherit the Seagen transaction and subsequently write down the asset's value, and sustained operations by repeatedly out-licensing pipeline assets abroad.

What this article tests. The primary question is not the validity of RemeGen's scientific findings. Clinical data published in the New England Journal of Medicine and presented at the European Society for Medical Oncology (ESMO) remains fully documented.⁸⁹ The central question is commercial: whether proprietary scientific discovery in China can construct a durable, self-sustaining biopharma business, or whether it yields a permanent treadmill where candidates are invented and licensed to Western pharma to fund operations without accumulating retained earnings.

The narrative trajectory proceeds as follows: how a manufacturer of traditional ointments established a modern biologics platform; a detailed examination of both core assets and potential competitive risks to their moats; an evaluation of historical capital allocation decisions; the unit economics of selling biologics within China's national reimbursement framework; an assessment of pipeline conversion rates for early-stage candidates; a comparison of management guidance against reported outcomes; and an analytical summary covering core metrics, key performance indicators, and investment thesis frameworks.

The analysis begins with the origins of the business and the source of its founding capital.

Subscribe on LinkedIn

↑ Back to Top

II. Yantai Roots & The Dual-Engine Founding (1993–2008–2020)

The origin story of RemeGen's biotech platform begins with hemorrhoid cream.

In 1993, 王威东 Wang Weidong founded 荣昌制药 Yantai Rongchang Pharmaceutical. Its primary commercial engine was a traditional Chinese medicine product line, most notably 荣昌肛泰 Rongchang Gangtai, an over-the-counter hemorrhoid treatment that became a household brand across northern China.¹⁰ It was a lucrative business with wide distribution into county-level pharmacies, but Wang recognized its structural limitations by the late 1990s. In China, generic and traditional formulations competed on price and distribution channels rather than proprietary intellectual property—a model vulnerable to any competitor offering lower prices or cheaper sales operations.

Rather than diversifying into adjacent consumer products, Wang sought a scientific partner to build a novel therapeutics business.

In 2008, he partnered with 房健民 Dr. Jianmin Fang. Born in 1962, Fang left China in 1993 to earn a doctorate in biology at Dalhousie University in Canada, followed by postdoctoral training at Harvard Medical School in the laboratory of Judah Folkman, a pioneer in tumor angiogenesis.¹⁰¹¹ Folkman's work on anti-angiogenic tumor therapy shaped Fang's research strategy. After returning to China, Fang designed 康柏西普 Conbercept, a VEGF-trapping fusion protein for wet age-related macular degeneration developed with Chengdu Kanghong, which became one of the first domestically invented biologics in China to surpass RMB 1 billion in annual sales.¹¹

Fang was 46 when he and Wang co-founded RemeGen in Yantai. The partnership established the company's dual foundation: Wang provided industrial capital, land, manufacturing expertise, and commercial infrastructure, while Fang brought Western-trained protein engineering capabilities and target selection strategy.

The choice not to be a me-too. During the 2010s, Chinese biotechnology focused heavily on PD-1 checkpoint inhibitors. Dozens of domestic developers targeted the same validated pathway, triggering intense price competition that drove domestic prices down to a small fraction of Western levels. RemeGen avoided the crowded PD-1 space entirely.

Instead, the company focused on more complex drug modalities. The first was a dual-target fusion protein designed to treat autoimmune diseases by neutralizing two B-cell survival factors: BLyS (also known as BAFF) and APRIL. While GSK's Benlysta—the first targeted lupus treatment approved globally—inhibits only BLyS, RemeGen's telitacicept incorporates the TACI receptor fused to an Fc domain to dual-inhibit both ligands simultaneously.

The second core platform was an antibody-drug conjugate (ADC), a targeted modality that pairs a monoclonal antibody with a cytotoxic payload via a chemical linker engineered to remain stable in systemic circulation and release its toxic agent selectively within tumor cells. RemeGen's disitamab vedotin pairs a humanised HER2 antibody binding a different epitope than trastuzumab with a monomethyl auristatin E payload via a cleavable valine-citrulline peptide linker.⁴

Building the factory before the drug. RemeGen also committed early capital to internal manufacturing rather than relying on contract development and manufacturing organizations. The company planned a 240,000-square-meter Yantai production complex with 162,000 liters of total fermentation capacity, designed to support annual output of 13.5 million fusion-protein vials and 4.5 million ADC vials.¹² For an unproven, pre-revenue biotech, this represented a substantial early capital allocation.

This infrastructure strategy also introduced governance complexities. An affiliated contract manufacturer, 迈百瑞 MabPlex, operates ADC manufacturing facilities across Yantai, Shanghai, and San Diego.¹² Related-party procurement between RemeGen and its corporate affiliates later drew regulatory scrutiny, becoming one of five primary inquiry areas raised by the Shanghai Stock Exchange in April 2024.¹³

Who actually controls this company? During the STAR Market listing review, regulators questioned the governance structure and ultimate decision-making control between the founding industrialist and scientific leadership.¹⁴ Disclosures revealed that RemeGen lacked a single controlling shareholder; instead, ten individuals acting in concert—including Wang and Fang, alongside Yantai partnership vehicles and offshore holding structures—maintained majority voting control. That concert group held 46.22% of equity at the time of the Shanghai A-share listing, a stake that subsequently adjusted to roughly 40.06%.¹⁴

This multi-party control structure served two contrasting functions. It shielded management from external takeover threats and short-term market pressures during prolonged development cycles, preserving strategic continuity. Conversely, it diffused personal accountability for capital allocation decisions, making it difficult for public shareholders to pinpoint ultimate responsibility when cash burn accelerated.

By late 2020, RemeGen possessed two clinical-stage biologics platforms and substantial manufacturing capacity, but zero commercial product revenue. To fund its expanding pipeline and infrastructure, the company turned to public equity markets just as global demand for biotechnology listings reached historical highs.

↑ Back to Top

III. The Autoimmune Engine: Telitacicept 泰爱® & Dual BLyS/APRIL Inhibition

Systemic lupus erythematosus is one of the most severe autoimmune diseases in medicine, and one of the least tractable. The immune system begins producing antibodies against the patient's own DNA and cellular machinery, attacking kidneys, joints, skin, blood vessels, and the brain. Striking women far more often than men—typically in early adulthood—the standard of care for decades remained essentially unchanged from the 1960s: corticosteroids and broad immunosuppressants, drugs whose long-term side effects including bone loss, infection, and metabolic damage are themselves disabling.

Between 1955 and 2011, regulators approved exactly one new drug specifically for lupus: Benlysta.

This was the market gap telitacicept was engineered to fill. In March 2021, China's 国家药品监督管理局 National Medical Products Administration (NMPA) granted it conditional approval for systemic lupus erythematosus—making it a domestically invented biologic for a disease where the global pharmaceutical industry had produced only one new therapy in half a century.

What the data actually showed. For years, Western skeptics argued that telitacicept's efficacy data relied on single-country Chinese trials with placebo response rates that appeared artificially favorable by international standards. That critique became harder to sustain in 2025, when pivotal Phase 3 results from China were published in the New England Journal of Medicine. The trial enrolled 335 patients with active disease across 42 Chinese hospitals, randomized one-to-one to receive weekly subcutaneous doses of 160 milligrams of telitacicept or a placebo alongside standard therapy. At week 52, 67.1% of telitacicept patients achieved an SRI-4 response, compared with 32.7% on placebo.⁸¹⁵

Two aspects of that trial stand out, pointing in opposite directions. First, the treatment gap of roughly 34 percentage points is unusually wide for lupus—a disease category crowded with failed clinical trials where placebo arms showed unexpected improvement. Furthermore, serious adverse events were lower in the treatment group than in the placebo group, at 7.2% versus 14.3%, consistent with a therapy where suppressing autoimmune activity reduces disease-driven hospitalizations by more than the drug's own immunosuppression adds risk.¹⁵ Conversely, the 32.7% placebo response rate remains low relative to Western lupus trials, and single-country data in an immunological disease with documented ethnic variations cannot substitute for a global study. These caveats do not invalidate the findings; rather, they demonstrate that the drug is clinically proven in China while remaining unproven globally—a distinction with immense strategic consequences.

The indication machine. The commercial logic of a B-cell-targeted therapy relies on broad applicability: because B cells drive multiple autoimmune pathologies, one molecule can serve multiple therapeutic markets. RemeGen executed directly on this strategy. Telitacicept expanded into rheumatoid arthritis, followed by generalized myasthenia gravis—approved on May 27, 2025, for adults with anti-acetylcholine-receptor-antibody-positive disease.¹⁶¹⁷ On June 8, 2026, the drug secured two additional regulatory approvals on a single day: conditional approval for IgA nephropathy and full approval for Sjögren's disease, marking its fourth and fifth authorized indications.¹⁸

The myasthenia gravis trial generated the franchise's most dramatic clinical figures. In a 114-patient Phase 3 study in China, 98.1% of patients receiving telitacicept achieved at least a three-point improvement on the MG-ADL activities-of-daily-living scale at week 24, compared with 12.0% in the placebo group; on the quantitative QMG scale, 87.0% achieved the five-point response threshold versus 16.0% for placebo.¹⁹ Efficacy of that magnitude in a neuromuscular disease warrants close scrutiny of sample size, blinding, and endpoint sensitivity before drawing definitive conclusions. A global Phase 3 trial spanning the United States, Europe, South America, and the Asia-Pacific region will provide the ultimate test, with topline results anticipated in the first half of 2027.²⁰

The commercial reality. Telitacicept generated RMB 1.387 billion in revenue in 2025, representing 41.9% growth year over year and establishing it as the larger of RemeGen's two primary commercial assets.²¹ By the end of 2025, the drug had secured formulary placement in more than 1,200 Chinese hospitals.²² Expansion of this scale four years post-launch, in a chronic condition requiring lifelong treatment, reflects substantive physician adoption rather than short-term channel loading. RemeGen also collected RMB 2.69 billion in cash from product sales in 2025, outpacing reported product revenue and confirming that revenue growth was supported by actual cash collections rather than expanding receivables.²³

Testing the moat. Management's primary commercial assertion—supported by sell-side consensus—is that telitacicept forms a first-in-class, multi-indication dual-target franchise insulated from competitive encroachment. Disclosures from the company's own operating history qualify this claim in three distinct ways.

First, RemeGen no longer retains commercial control of telitacicept outside Greater China. On June 25, 2025, the company licensed global ex-Greater China rights to Vor Bio, a small Nasdaq-listed firm that had months earlier begun winding down its proprietary cell-therapy programs.²⁴ The financial terms reflect RemeGen's constrained bargaining position: out of an announced US$125 million total consideration, only US$45 million was paid in upfront cash, with the remaining US$80 million delivered in equity warrants exercisable at US$0.0001.²⁴ For the international rights to a compound backed by five domestic approvals and Phase 3 data published in the New England Journal of Medicine, US$45 million in upfront cash signals balance-sheet pressure rather than premium asset valuation.

Second, the dual BLyS/APRIL mechanism is no longer exclusive to RemeGen, and the company is not leading the race to commercialize the class in Western markets. Vera Therapeutics presented positive Phase 3 ORIGIN trial data for its competing drug, atacicept, in IgA nephropathy at the American Society of Nephrology Kidney Week in November 2025—with simultaneous publication in the New England Journal of Medicine—showing a 46% reduction in proteinuria and a 42% reduction relative to placebo as it advanced toward a U.S. regulatory filing.²⁵ Meanwhile, Vertex Pharmaceuticals is progressing povetacicept, acquired through its purchase of Alpine Immune Sciences, along the same pathway. Consequently, telitacicept's first-mover advantage remains confined to China, while rival mechanisms may reach Western markets first.

Third, pricing dynamics constrain long-term unit economics. When telitacicept was added to China's 国家医保目录 National Reimbursement Drug List (NRDL) in December 2021, the price per 80-milligram vial was reduced from RMB 2,586 to RMB 818.80—a 68.34% cut.²⁶ This price reduction brought the annual cost of therapy down from approximately RMB 269,000 at the launch list price of RMB 5,172 per box to roughly RMB 79,000.²⁷ While volume growth has been robust, it was achieved only after accepting a two-thirds reduction in price to secure national market access.

Where that leaves the claim. The historical record does not disprove telitacicept's scientific validity; its regulatory approvals, clinical trial evidence, and revenue trajectory are real. However, the evidence redefines the boundaries of the investment thesis. Telitacicept is a viable, multi-indication commercial franchise inside China, protected primarily by the substantial capital required to maintain domestic rheumatology and neurology sales forces rather than by insurmountable global patent moats. Externally, RemeGen's participation in international commercialization has been reduced to a royalty and milestone structure managed by a third party. The decisive test will arrive in the first half of 2027: if global Phase 3 trial data in myasthenia gravis prove positive and enable international filings, the ex-China licensing deal will yield tangible value; if the trial fails, RemeGen's international upside remains limited to equity warrants in a micro-cap partner.

The oncology franchise reflects a similar strategic trajectory—with the key difference that its international licensing partner has already abandoned the asset.

↑ Back to Top

IV. The Oncology Engine: Disitamab Vedotin 爱地希® & The ADC Platform War

In June 2021, the NMPA granted conditional approval to disitamab vedotin for HER2-overexpressing locally advanced or metastatic gastric cancer in patients who had failed at least two prior chemotherapy regimens.⁴²⁸ It was the first antibody-drug conjugate (ADC) discovered in China to reach the domestic market. Two months later, Seagen—then a leading pure-play ADC developer—agreed to pay US$200 million upfront and up to US$2.4 billion in milestone payments for licensing rights outside RemeGen's Asian territory.⁷²⁹

For Chinese biotechnology, that August 2021 agreement marked a pivotal moment: a domestic firm had licensed an internally discovered ADC to an established Western developer in a transaction carrying headline consideration of US$2.6 billion, resetting domestic valuation expectations across the sector.

Five years later, however, the asset sits on Pfizer's balance sheet written down by US$1.6 billion.³⁰

Why HER2 again? HER2 is a growth-factor receptor overexpressed on the surface of certain tumor cells. Although targeted therapies against HER2 date back to Herceptin's approval in 1998, developing another HER2 agent offered two strategic advantages. First, an ADC uses the antibody primarily as a targeted delivery vehicle, enabling developers to target different epitopes and tumor types. Second, tumors with moderate or low HER2 expression—insufficient to benefit from trastuzumab alone—can still internalize enough conjugate to deliver a lethal cytotoxic payload.

Disitamab vedotin's primary commercial footprint emerged not in breast cancer, where competition was dense, but in urothelial carcinoma, or bladder cancer. HER2 expression is common in urothelial tumors, a setting long reliant on platinum-based chemotherapy with limited durability of response. After securing approval in China for platinum-refractory metastatic urothelial cancer, RemeGen pursued the larger first-line indication.⁴

The data that should have settled it. At the European Society for Medical Oncology congress in October 2025, RemeGen presented results from the RC48-C016 Phase 3 trial. The study enrolled 484 patients with previously untreated HER2-expressing locally advanced or metastatic urothelial carcinoma, randomized to receive either disitamab vedotin combined with the PD-1 antibody toripalimab or platinum-based chemotherapy. Median progression-free survival reached 13.1 months for the combination arm versus 6.5 months for chemotherapy, representing a hazard ratio of 0.36. Median overall survival nearly doubled to 31.5 months compared with 16.9 months in the chemotherapy control group, with a hazard ratio of 0.54.⁹³¹

In most oncology categories, nearly doubling median overall survival in a first-line metastatic setting would trigger rapid global commercialization.

Facing Goliath — and Goliath's cousin. The global benchmark for HER2 ADCs remains Daiichi Sankyo and AstraZeneca's Enhertu, a trastuzumab-deruxtecan conjugate carrying a topoisomerase-I payload that expanded rapidly across breast, gastric, and HER2-low indications. Disitamab vedotin's differentiation claims rest on a lower reported rate of interstitial lung disease—a key safety liability for Enhertu—and an established foothold in urothelial cancer.

Domestically, the competitive environment has intensified since 2021. Hengrui Pharmaceuticals is advancing SHR-A1811, Kelun-Biotech partnered its ADC portfolio with Merck, and Bio-Thera alongside other domestic developers entered the space. Within five years, China's ADC landscape shifted from RemeGen holding the sole approved domestic asset to a crowded field of competing programs—mirroring the intense domestic competition that previously reshaped the market for PD-1 antibodies.

The disconfirming evidence: how the Seagen deal actually ended. Pfizer completed its US$43 billion acquisition of Seagen on December 14, 2023.³² Following the acquisition, Pfizer audited Seagen's inherited pipeline alongside its existing portfolio. Disitamab vedotin faced a clear strategic overlap: Pfizer already owned Padcev (enfortumab vedotin), an established vedotin ADC that held a dominant position in advanced urothelial carcinoma. Consequently, further clinical investment in disitamab vedotin for bladder cancer directly risked cannibalizing Padcev's market share.

Enrollment in the Pfizer-sponsored global trial was halted in December 2024, with Pfizer confirming the permanent stoppage was driven by strategic business considerations rather than safety signals.³³ Pfizer recognized a US$200 million impairment on the asset in its fourth-quarter 2024 results, citing emerging competition.³⁴ In its fiscal 2025 Form 10-K, Pfizer recorded an additional US$1.6 billion impairment on disitamab vedotin—the single largest component of its US$3.6 billion in-process research and development write-downs that year. Pfizer explicitly noted that strong clinical readouts, indication expansions, and higher long-term revenue projections for Padcev reduced the expected commercial value of disitamab vedotin in bladder cancer.³⁰

This sequence underscores a structural risk in cross-border out-licensing. Disitamab vedotin's global trial program was not terminated due to clinical failure; its domestic first-line Phase 3 results were positive. Instead, development halted due to portfolio overlap at the licensee—a risk that cannot be mitigated by trial design or upfront deal terms. Headline out-licensing figures represent potential milestone payments contingent on a Western partner's continued strategic alignment, which remains subject to corporate reprioritization.

What RemeGen actually received. RemeGen received the initial US$200 million upfront payment upon closing the transaction. Subsequent milestone receipts were not itemized separately in public disclosures, and the headline figure of US$2.4 billion in potential milestones for the bladder cancer program is no longer realizable. The initial strategic assumption—that an international partner would fund and execute global development—was neutralized when Pfizer halted funding.

Commercial performance, and what it implies. In China, disitamab vedotin generated RMB 720 million in product revenue in 2024, representing 36% year-over-year growth.³⁵ In 2025, revenue increased 22.45% to RMB 884 million.²¹ By year-end 2025, the drug secured formulary access at more than 1,050 medical institutions, followed by an additional NMPA approval in HER2-low metastatic breast cancer in March 2026.²²²¹

The deceleration in revenue growth from 36% to 22.45% highlights divergent commercial dynamics across RemeGen's two lead assets. Telitacicept, operating in a chronic autoimmune market with fewer direct domestic competitors, grew 41.9% in 2025. By contrast, disitamab vedotin operates in an oncology market characterized by shorter treatment durations and expanding domestic competition, resulting in slower expansion.

The operational record presents a clear picture of the ADC franchise: the underlying technology is validated, the clinical data in urothelial cancer are robust, and domestic operations contribute positive gross margins. However, the premise that the 2021 Seagen transaction established disitamab vedotin as a premier global asset is qualified by subsequent events. Outside Greater China, disitamab vedotin remains an unpartnered program that requires internal funding to advance—a financial requirement that directly impacts RemeGen's broader capital structure.

↑ Back to Top

V. Capital Allocation, Dual Listing, & The Seagen/Pfizer Paradox (2020–2026)

There is a specific kind of corporate document that tells you more about a company than any earnings release. On 29 April 2024, the Shanghai Stock Exchange sent RemeGen a supervisory letter demanding explanations across five areas: its core business operations, its interest-bearing debt, its production capacity, its related-party procurement, and its notes payable and prepayments.¹³ Exchanges do not send those letters to companies they find easy to understand.

To see why the letter arrived, run the capital history forward.

The raising years. RemeGen listed on the Main Board of the 香港联交所 Stock Exchange of Hong Kong on 9 November 2020 at HK$52.10 per share, raising HK$3.99 billion — about US$515 million before the over-allotment, roughly US$590 million after — the largest primary biopharmaceutical listing globally that year.⁵³⁶ Sixteen months later it listed on the STAR Market on 31 March 2022 at RMB 48 per share, raising RMB 2.612 billion gross and RMB 2.506 billion net.⁶³⁷ Note the detail that is easy to skip: RemeGen had originally sought RMB 4 billion in the A-share offering and cut the target to RMB 2.6 billion.⁶ Even at the top of the cycle, the market was already pushing back.

Add the Seagen upfront and RemeGen assembled well over US$1 billion of gross proceeds across roughly eighteen months.

The burn. What followed was not a gradual drawdown but an acceleration. Revenue did grow — RMB 772 million in 2022, RMB 1.083 billion in 2023, RMB 1.717 billion in 2024.³⁸ But spending grew faster and from a higher base. Cumulative R&D through the third quarter of 2024 reached RMB 4.62 billion; combined selling and administrative expense over the same period exceeded RMB 3.3 billion.³⁹ Cumulative losses from 2020 through 2024 totalled roughly RMB 4.4 billion against approximately RMB 6.3 billion raised in the two IPOs.³⁹

By the end of 2024 the arithmetic had turned genuinely uncomfortable. Net loss for the year was RMB 1.468 billion. Operating cash flow was negative RMB 1.114 billion. Cash and equivalents stood at RMB 762 million — less than eight months of the prior year's operating burn. Short-term borrowings had risen to RMB 1.084 billion and long-term borrowings to RMB 1.482 billion. The asset-liability ratio had climbed from 37.82% to 63.88% in a single year.¹³

A pre-profit biotech financing operations with bank debt is a structurally awkward position. Debt demands cash interest on a fixed schedule; drug development produces cash on no schedule at all. RemeGen's interest burden reached roughly RMB 72 million in 2024.³⁸ For context, that is not a large number against revenue — but it is a large number against a company with RMB 762 million of cash and no profits.

The financing that did not happen. On 29 March 2024, RemeGen announced a plan to issue A-shares to specified investors for up to RMB 2.55 billion.⁴⁰ By 25 July 2024 the plan had been revised down to RMB 1.953 billion.⁴¹ It was never completed.⁴²

That failure is itself an important data point. In a market where Chinese biotech equity had gone cold, RemeGen could not place a private placement at a size it considered acceptable — which is a market verdict on the business model, delivered before management reached the same conclusion.

What happened instead: the pivot to selling the pipeline. With the A-share route closed, RemeGen executed three transactions in thirteen months that changed the company's financial trajectory.

On 22 May 2025 it placed 19 million H-shares at HK$42.44, raising net proceeds of roughly HK$796 million.¹³ Five weeks later came the Vor Bio telitacicept licence. On 19 August 2025 it licensed RC28-E, its ophthalmology candidate, to Japan's 参天製薬 Santen Pharmaceutical for Greater China plus much of Southeast Asia — RMB 250 million upfront, up to RMB 520 million in development and regulatory milestones and up to RMB 525 million in sales milestones.⁴³ And on 12 January 2026, at the JP Morgan Healthcare Conference, AbbVie agreed to pay US$650 million upfront and up to US$4.95 billion in milestones for RC148 outside Greater China, with tiered double-digit royalties.²⁴⁴

The results these produced. In 2025, revenue rose 89.36% to RMB 3.251 billion. Product sales grew 35.8% to RMB 2.307 billion and technology licensing contributed RMB 895 million. The company reported net profit attributable to shareholders of RMB 710 million — its first profitable year.²³

Here is where independent analysis has to depart from the press release. Profit excluding non-recurring items was RMB 68 million, not RMB 710 million.²³ The gap — RMB 642 million — came predominantly from revaluation of financial assets, which is to say principally from marking up the Vor Bio warrants as Vor Bio's share price rose.²³ RemeGen's 2025 profit was, in substance, a mark-to-market gain on equity received in lieu of cash from a licensing counterparty.

The Q1 2026 accounts make the same point in miniature: revenue of RMB 656 million, reported net profit of RMB 328 million, and a loss of RMB 35 million once non-recurring items are stripped out.⁴⁵

The Santen deal deserves a second look. Notice what it was: RemeGen sold the Chinese and Asian rights to its own ophthalmology asset. Every other transaction sold rights abroad while retaining the home market. This one sold the home market. The most plausible reading is that RemeGen concluded it could not afford to build a third commercial organisation — ophthalmology sells through a completely different physician channel than rheumatology or oncology — and monetised the asset rather than under-resourcing it. That is a defensible decision. It is also an admission about the limits of the company's commercial reach, and it permanently caps what RC28-E can ever contribute to RemeGen's domestic revenue.

A cost the company also chose to stop paying. On 18 May 2026, RemeGen announced it was discontinuing RC88 and RC108 and cutting funding to RC118, citing clinical efficacy below expectations and a deteriorating competitive landscape. RC88 and RC108 alone represented at least RMB 522 million of sunk investment; in total roughly RMB 1.05 billion of previously allocated funds were redirected, principally toward accelerating RC148.⁴⁶

Weighed honestly, this is capital allocation with two faces. Killing failing programmes and concentrating behind the asset a global partner was willing to pay US$650 million for is exactly what a disciplined allocator should do, and doing it decisively is better than the industry norm of letting weak assets limp forward. But the write-off is also the bill for an earlier decision to fund a broad pipeline from IPO proceeds without the earnings to support it. The reallocation is not evidence of foresight; it is evidence of correction.

Where the balance sheet stands now. As of 30 June 2026, cash stood at approximately RMB 3.84 billion.³ That is a genuinely transformed position — roughly five times the end-2024 level, and enough to fund several years of the current burn. It also arrived almost entirely from one payment from one partner for one unapproved asset.

The investor question is therefore not whether RemeGen is currently solvent. It plainly is. The question is what the six-year record establishes about how this company funds itself. On the evidence: RemeGen has never funded a full year of its own operations from product sales. Every period of financial stability has been created by an external cheque — an IPO, a placement, or a licence. Management now says 2026 will break even excluding business-development income.²¹ That statement, if delivered, would be the first genuine break in the pattern. It is the single most consequential thing to watch, and Section VIII returns to whether this management team's prior guidance earns the benefit of the doubt.

Which brings us to why self-funding is so hard in the first place. It is not that RemeGen's drugs do not sell. It is what it costs to sell them.

↑ Back to Top

VI. Commercialization Economics & The Chinese Healthcare Squeeze

Consider the operational reality of biopharmaceutical sales in China. When a sales representative arrives at a 三甲医院 tertiary-A hospital in a provincial capital such as Zhengzhou or Chengdu, national regulatory approval provides only the legal right to sell. Before a doctor can prescribe telitacicept, the drug must clear the individual hospital's pharmacy and therapeutics committee—a process that often takes months and must be repeated institution by institution across thousands of hospitals.

This institutional bottleneck receives relatively little attention outside drug distribution circles, yet it explains much of the commercial economics of Chinese biopharmaceuticals.

The decision to sell directly. RemeGen could have partnered with a major distributor such as 国药控股 Sinopharm, 上海医药 Shanghai Pharmaceuticals, or an established multinational drugmaker to trade gross margin for immediate distribution reach. Instead, the company chose to build its own field organization.

By the end of 2025, that commercial organization numbered roughly 1,400 sales personnel, divided into two specialized teams: approximately 900 focused on autoimmune indications and 500 on oncology.²² This separation reflects distinct clinical workflows. Representatives calling on rheumatologists and neurologists market a chronic maintenance therapy centered on flare prevention and long-term steroid reduction. Representatives engaging oncologists manage line-of-therapy positioning against rival cancer regimens. Operating two specialized sales forces requires maintaining two separate fixed cost bases against product revenue that crossed RMB 2 billion only in 2025.

The institutional footprint built by these field teams represents a core operational asset. By the end of 2025, telitacicept achieved formulary access at more than 1,200 hospitals, while disitamab vedotin reached more than 1,050 institutions.²² Each listing functions as reusable commercial infrastructure through which future internal pipeline candidates can eventually be distributed at low incremental expense—the primary structural argument for constructing a direct sales force.

The cost of commercialization. Selling expenses rose 17.15% in 2025 to RMB 1.111 billion, representing 34.19% of total reported revenue.²³ Because total revenue included non-recurring licensing payments, evaluating sales expenditure against organic product sales provides a clearer picture: selling costs absorbed nearly half of every yuan generated from drug sales. When combined with administrative expenses of RMB 364 million, commercial operations and corporate overhead consumed roughly two-thirds of underlying drug sales before allocating a single yuan to research and development.²³

Commercial efficiency showed initial signs of progress in early 2026. In the first half of 2026, the selling expense ratio relative to product revenue fell to approximately 41%—a seven percentage point drop year over year—while product gross margin reached 83.7%.³ That gross margin reflects the financial advantage of RemeGen's in-house manufacturing strategy. By producing its own fusion proteins and executing its own antibody-drug conjugations in Yantai, the company avoids paying contract manufacturing markups under government-capped drug prices.

However, a substantial gap persists between an 83.7% gross margin and a self-funding business model. That gap is driven entirely by operating expenses—specifically the ongoing cost of securing and maintaining hospital-level stocking and prescriptions.

Reimbursement dynamics and pricing power. Price compression forms the second component of commercial margin pressure. China's 国家医疗保障局 National Healthcare Security Administration (NHSA) conducts annual negotiations for inclusion on the National Reimbursement Drug List (NRDL). As the dominant payer for specialty therapeutics in China, the NHSA holds substantial pricing power; declining reimbursement status preserves list price but eliminates access to the vast majority of patient volume.

RemeGen has navigated multiple negotiation cycles. Following steep initial price cuts upon NRDL entry, recent renewal rounds proved less severe. In the negotiation cycle taking effect on January 1, 2026, price cuts for the company's two lead products were held to roughly 10%, outperforming market expectations of a 15% reduction and extending coverage across four indications, including generalized myasthenia gravis for the first time.²¹⁴⁷

This pricing structure yields two key strategic implications. First, manageable discount rates are critical to financial sustainability: a 10% price reduction can be offset by volume growth exceeding 30%, whereas a 25% cut severely degrades operating margins. Second, reimbursement inclusion is what creates patient volume in the first place. Prior to NRDL listing, telitacicept's annual list price restricted adoption to a small fraction of potential patients. Price concessions and market access are structurally interdependent.

Hospital budget constraints. Beyond national pricing, two institutional mechanisms constrain domestic revenue expansion. Under China's zero-markup pharmacy policy, public hospitals no longer earn markups on drug sales, turning hospital pharmacies from profit centers into cost centers. Simultaneously, Diagnosis-Related Group (DRG) and Diagnosis Intervention Packet (DIP) payment reforms allocate fixed reimbursement caps per treatment episode.

Consequently, prescribing an expensive biologic directly impacts a hospital's fixed operating budget. Clinical departments ration high-cost drugs internally, forcing sales personnel to compete not only for clinical mindshare but also for finite departmental budget allocations. These budgetary controls explain why regulatory approvals and NRDL listings convert into realized revenue gradually, underscoring hospital formulary access counts as a critical operating performance metric.

Evaluating the commercial model. The optimistic case posits that RemeGen has constructed a reusable commercial foundation: two specialized field forces covering over 1,000 hospitals each, capable of supporting five existing approved indications and future internal launches with expanding operating leverage. This view is supported by the first-half 2026 expense reduction and the RMB 2.69 billion in cash collected from product sales in 2025.²³

The cautious case holds that the sales infrastructure represents a high fixed cost structure relative to current scale, that pricing remains constrained by single-payer negotiations, and that local hospital budget rationing restricts volume growth, slowing the operational leverage required to fund ongoing R&D.

Both perspectives are supported by reported results, making the selling-expense ratio a key metric for monitoring corporate execution. While first-half 2026 efficiency gains indicate progress, sustained operational leverage over multiple years will be required to demonstrate self-funding capability.

Beyond domestic commercialization, RemeGen has increasingly relied on a secondary strategy to manage domestic margin pressure: out-licensing internally developed assets to international partners.

↑ Back to Top

VII. The Pipeline & Dark-Horse Optionality (RC28, RC148, & Beyond)

On May 18, 2026, RemeGen published an announcement that drew minimal market reaction, with its stock rising 0.44% to close at RMB 112.47 the following session.⁴⁶ The disclosure confirmed the termination of two clinical candidates, RC88 and RC108, alongside reduced funding for a third, RC118, citing clinical efficacy below expectations and an increasingly crowded competitive landscape.⁴⁶

That decision provides an empirical baseline for evaluating RemeGen's broader clinical pipeline.

When RemeGen listed in 2020, it presented a portfolio of more than ten candidates beyond its two primary commercial assets. Six years later, the observable outcomes reflect standard industry conversion dynamics: one candidate, RC148, secured a major global licensing partner; another, RC28-E, was licensed regionally on modest terms; three were discontinued or defunded; and the remainder have yet to generate disclosed commercial value. While consistent with broader biopharmaceutical attrition rates, this track record forms the appropriate framework for assessing prospective pipeline assets.

RC28-E: The ophthalmology bet and commercial trade-offs. RC28-E is a dual-target fusion protein designed to block both VEGF and FGF, expanding on Dr. Jianmin Fang's earlier work on Conbercept. By simultaneously inhibiting abnormal blood vessel proliferation and tissue scarring, the compound aims to treat wet age-related macular degeneration and diabetic macular edema while reducing the injection frequency required by standard anti-VEGF therapies. Development has advanced through domestic regulatory channels, with the NMPA accepting the filing for diabetic macular edema in September 2025, followed by the submission for wet age-related macular degeneration.²¹

However, the commercial value of RC28-E for RemeGen shareholders remains structurally capped. By licensing Greater China and broader Southeast Asian rights to Santen Pharmaceutical in exchange for an upfront payment in the low hundreds of millions of renminbi plus milestones, RemeGen converted its most advanced secondary pipeline candidate into a royalty stream within its home market—the single geography where it operates an established direct sales force. Consequently, future domestic approvals will trigger milestone receipts for RemeGen but commercial launches for Santen, reflecting a decision to monetize the asset rather than fund a third specialized field force.

RC148: The bispecific oncology asset. RC148 is a bispecific antibody targeting both PD-1 and VEGF, a mechanism class that emerged as a major focus of global oncology licensing following strong early lung cancer readouts from Chinese-originated programs. AbbVie's primary strategic rationale centers on combining RC148 with its expanding antibody-drug conjugate portfolio.² RemeGen had five domestic clinical trials underway for RC148 around the time of the transaction,²¹ and subsequently redirected capital freed from the terminated RC88 and RC108 programs to accelerate its development.⁴⁶

While the AbbVie agreement demonstrates the capability of RemeGen's research team to discover molecules that attract major international buyers, it does not confirm clinical efficacy. AbbVie acquired an option on an unapproved clinical-stage asset within a competitive target class. While out-licensing validates early-stage deal-making capability, it remains distinct from converting pipeline candidates into approved, revenue-generating global products.

Earlier-stage candidates and R&D allocation. Beyond RC148, management has highlighted earlier-stage pipeline candidates, including RC278 (targeting CDCP1) and RC288 (a PSMA/B7H3 bispecific ADC), alongside a next-generation iteration of telitacicept.²¹ Evaluating these early assets requires context on overall research expenditure: research and development expenses declined 20.85% in 2025,²³ followed by a further 36.19% year-over-year reduction in the first quarter of 2026.⁴⁵

Whether this spending reduction represents disciplined pipeline prioritization or broader budget retrenchment cannot be conclusively determined from external filings alone. Reallocating resources behind a candidate backed by a major international upfront payment aligns with rational capital allocation. However, because biopharmaceutical discovery operates on multi-year development cycles, the ultimate impact of reduced R&D expenditure will become visible in pipeline output only several years later.

↑ Back to Top

VIII. Management Credibility & Skeptical Investor Stress Test

On February 6, 2025, RemeGen announced that 何如意 He Ruyi had resigned from every position he held at the company.³⁹

To understand why that departure mattered requires examining his background. Born in 1961, He spent 17 years at the U.S. Food and Drug Administration before returning to China as chief scientist at the Center for Drug Evaluation, the NMPA unit that reviews every new drug application in the country. When he joined RemeGen as chief medical officer in January 2020—the year of its Hong Kong initial public offering—the appointment signaled the company's global ambitions, as domestic trial oversight rarely required an executive with senior FDA and CDE experience. In August 2024, he transitioned to chief strategy officer, and six months later he departed, citing personal career development.³⁹

His departure was part of a broader executive transition. President 傅道田 Fu Daotian departed in 2023 upon term expiry, and the chief financial officer subsequently resigned, citing personal work changes.¹³ Three senior executive departures within roughly two years—occurring precisely as the balance sheet faced severe pressure and the international strategy underwent revision—represent an operational pattern that warrants careful evaluation.

The executive leadership. Chairman 王威东 Wang Weidong represents the company's industrial leadership. His track record reflects aggressive capital deployment: raising substantial equity during market peaks, constructing manufacturing capacity ahead of commercial demand, and simultaneously funding a broad clinical pipeline and a 1,400-person commercial field force. That strategy yielded two approved biologics and an established domestic franchise. However, it also generated the strained balance sheet of late 2024. Raising approximately RMB 6.3 billion across two public listings, expending those funds, writing off over RMB 500 million in clinical pipeline investments, and ultimately abandoning a proposed private placement reflect significant capital allocation challenges during that expansion phase.³⁹⁴⁶

Chief Executive and Chief Scientific Officer 房健民 Dr. Jianmin Fang serves as the primary scientific architect. His discovery record includes Conbercept, telitacicept, and disitamab vedotin—three first-in-class molecules in China. The AbbVie out-licensing agreement demonstrates continued productivity from his research group. Conversely, RemeGen's international clinical timelines have repeatedly lagged initial projections, and the strategy of pursuing global development through Seagen ultimately shifted to licensing its lead autoimmune compound to a smaller partner that delivered the majority of initial consideration in equity warrants.

Fang also represents a central key-person consideration. The corporate research strategy, drug modality choices, and pipeline credibility among international counterparties remain closely tied to a single chief scientist who turned 64 in 2026, while formal executive succession plans have not been publicly disclosed.

Guidance tracking and execution. Evaluating management performance requires comparing public guidance against reported financial and operational outcomes.

For 2025, management targeted approximately 30% growth in domestic commercial product sales. Actual domestic product revenue reached RMB 2.271 billion, representing 33.7% growth and outperforming the target.²¹

For 2026, management guided toward a decelerated growth rate of roughly 25%, citing reimbursement price adjustments and the timing of new indication launches, while projecting operational breakeven excluding business-development income.²¹ First-half 2026 results presented a mixed picture: underlying product sales grew 22.3% year-over-year—slightly below the full-year target—though major indication approvals secured in June 2026 provide additional commercial tailwinds for the second half.³ Full-year reporting in early 2027 will determine whether both guidance targets were achieved.

Over a longer horizon, executive forecasts have proven less consistent. For five years, management maintained that commercial expansion would fund ongoing operations. In practice, corporate operations were sustained through a sequence of capital raises: an initial public offering in Hong Kong, a secondary listing in Shanghai, a secondary share placement, bank credit facilities, and three major out-licensing transactions. Operating self-sufficiency was repeatedly projected yet repeatedly deferred.

Governance and oversight. The Shanghai Stock Exchange's April 2024 supervisory letter highlighted key corporate governance areas. Regulatory inquiries regarding interest-bearing debt typically emerge when leverage metrics diverge from operating cash flows, while reviews of related-party procurement examine transactions involving affiliated manufacturing entities. Although neither inquiry resulted in formal regulatory sanctions, both areas remain relevant monitoring points for an enterprise operating within an affiliated ecosystem.

Additionally, the ten-member concert-party voting agreement provides corporate stability against external acquisition threats. However, it also diffuses individual voting control, leaving the company without a single controlling shareholder accountable for capital allocation outcomes.

The short thesis. A skeptical investor evaluating RemeGen in late 2026 would highlight several operational risks.

Reported 2025 net profit relied significantly on mark-to-market gains from equity warrants received in a licensing transaction rather than core operating cash flow—an accounting outcome subject to counterparty share price volatility. First-half 2026 net profit similarly reflected upfront licensing income recognized in a single reporting period, representing non-recurring revenue. Meanwhile, underlying product sales growth decelerated from the high 30s to the low 20s, and research expenditures were reduced for two consecutive years despite management framing the pipeline as the primary driver of long-term value. Executive turnover, historical pipeline write-offs disclosed in May 2026, and reliance on a small-cap partner for international autoimmune trials whose Phase 3 data remains a year away further compound operational uncertainty.

The long thesis. Conversely, a supportive investment thesis emphasizes that RemeGen successfully commercialized two internally invented biologics across more than 1,000 hospitals each, achieving sales growth rates rare among domestic biopharmaceuticals. Product gross margins exceeding 80% validate the early investment in internal manufacturing capacity, while selling expense ratios have begun to decline. Furthermore, securing major transactions with Seagen, Vor Bio, and AbbVie demonstrates that international pharmaceutical companies recognize value in the platform's research output. Supported by approximately RMB 3.84 billion in cash reserves as of mid-2026, the company possesses a clear runway toward operational breakeven.³

Strategic synthesis. The divergence between these two perspectives centers on how out-licensing transactions are characterized. Whether international licensing functions as an enduring commercial business model or as a temporary financing mechanism remains the central question. For RemeGen, out-licensing has historically served both functions, with transaction proceeds acting primarily as an alternative capital source to fund ongoing operations.

↑ Back to Top

IX. Strategic Frameworks: 7 Powers, Porter's 5 Forces, & Risk Radar

Strategic frameworks are useful only when applied dispassionately, which requires discounting the structural moats a company might claim. Evaluating RemeGen through Hamilton Helmer's 7 Powers framework reveals a competitive position considerably narrower than its corporate narrative suggests.

Cornered resource. This is RemeGen's strongest power, but it remains structurally bounded. The company holds composition-of-matter and process patents covering its proprietary TACI-Fc fusion protein and HER2 antibody-drug conjugate. Inside China, these patents offer strong protection through their statutory life. Globally, however, that protection is less exclusive: Western rivals are advancing competing dual-target BLyS/APRIL inhibitors, with one competitor already publishing positive Phase 3 data and preparing for a U.S. regulatory submission.²⁵ Furthermore, by licensing ex-China rights to international partners, RemeGen converted its core intellectual property into royalty claims rather than directly controlled commercial territory. Ultimately, the true cornered resource may be the scientific team led by Dr. Jianmin Fang—a human asset that cannot be capitalized on a balance sheet and carries key-person risk.

Process power. Moderate and improving. Investing early in proprietary fusion protein fermentation and ADC conjugation facilities before commercial validation was a capital-intensive strategy. That infrastructure yielded tangible cost advantages, reflected in an 83.7% product gross margin achieved without reliance on contract manufacturers.³ However, biologics manufacturing capabilities are not strictly proprietary; the rapid expansion of China's contract development and manufacturing sector allows competitors to lease comparable capacity without incurring heavy upfront capital expenditures.

Switching costs. Moderate, but divided between the two commercial engines. In chronic autoimmune indications such as lupus, myasthenia gravis, and Sjögren's disease, physicians are reluctant to switch patients once disease control is established, creating durable treatment persistence for telitacicept. In oncology, switching costs are substantially lower, as treatment regimens frequently change across lines of therapy based on disease progression and emerging clinical trial data.

Scale economies. Weak. While RemeGen's 1,400-person field organization provides targeted reach across Chinese hospitals, it lacks scale compared with major domestic pharmaceutical companies and global multinationals. Any scale advantage remains localized to sales force density within domestic rheumatology and urology networks.

Network effects. Absent. Biopharmaceutical products do not gain intrinsic utility as user adoption expands. Prescriber familiarity creates habitual prescribing patterns, but this represents brand loyalty rather than a true network effect.

Counter-positioning. Weak. Counter-positioning requires incumbents to be structurally disincentivized from responding due to business-model conflict. Major pharmaceutical incumbents face no structural barriers preventing them from competing directly with RemeGen using superior development capital and global commercial infrastructure. Ironically, the only instance of counter-positioning operated against RemeGen, when Pfizer halted global trials for disitamab vedotin to avoid cannibalizing its existing urothelial cancer franchise.

Branding. Moderate and geographically restricted. Trademarks for 泰爱 and 爱地希 hold established clinical equity among Chinese specialists involved in domestic clinical trials. Outside China, however, brand recognition is negligible.

Porter's 5 Forces, applied to RemeGen's primary operating market:

Buyer power is extreme. China's National Healthcare Security Administration operates as a single-payer monopsony, conducting mandatory annual price negotiations for reimbursement listing, while public hospitals enforce strict episode-based budget caps. This single constraint accounts for much of the gap between RemeGen's high gross margins and its historical operating losses.

Threat of new entrants is high. Declining development costs for biologic therapies in China have drawn intense capital into RemeGen's core modalities. Competing domestic HER2 ADC programs that did not exist at launch now contest the market, directly contributing to the growth deceleration observed in the oncology franchise.

Rivalry is intense. Domestic competition is increasingly fought on clinical trial execution and indication expansion speed rather than price alone, with first-line approvals capturing dominant market share.

Supplier power is low. Standard inputs—including cell culture media, bioreactor consumables, and payload linkers—are widely commoditized across multiple vendors.

Threat of substitutes is a long-term risk. Emerging therapeutic approaches, such as CD19-targeted cell therapies demonstrating drug-free remission in severe autoimmune cases, present a potential paradigm shift away from chronic weekly biologic administration over time.

The risk radar, restricted to material operational variables:

Ex-China clinical execution. With international trials for myasthenia gravis and Sjögren's disease assigned to Vor Bio, any clinical setback would eliminate global royalty upside and invite scrutiny regarding whether domestic trial results translate internationally.²⁰

Reimbursement price erosion. Annual NRDL review cycles create continuous pricing pressure, ensuring that commercial volume expansion is periodically offset by price concessions.

Refinancing and dilution. Although recent out-licensing inflows provided cash runway through mid-2026, the historical pattern of recurring equity and debt raises indicates that any extended pause in licensing income could renew balance-sheet stress.

Key-person concentration. Scientific discovery and corporate strategy remain highly reliant on core technical leadership without a formalized public succession structure.

Partner portfolio risk. Disitamab vedotin demonstrated that licensee strategy can override asset potential. RemeGen remains exposed to strategic reprioritization at AbbVie and financial constraints at Vor Bio—risks outside its operational control.

Geopolitical exposure. Increasing scrutiny of cross-border biotechnology transactions and potential legislative restrictions in Western markets pose ongoing risks to out-licensing deal flow.

↑ Back to Top

X. Playbook & Investing Lessons

One: Two engines diversify clinical risk, not financial risk. The dual-platform strategy fulfilled its primary design objective at the scientific level. When Pfizer halted global development of disitamab vedotin in 2024 and 2025, expanding regulatory approvals and commercial sales for telitacicept sustained the corporate story. Conversely, when the autoimmune franchise required international validation, the oncology candidate RC148 secured a US$650 million upfront payment from AbbVie. That balance represents genuine asset-level risk mitigation.

However, operating two separate platforms did not reduce capital requirements. Maintaining distinct autoimmune and oncology modalities required funding two dedicated sales forces, financing parallel registrational trial programs, and contesting two separate competitive landscapes. RemeGen's operating losses through 2024 were driven in part by the demands of maintaining this dual structure. Portfolio diversification mitigates clinical risk, but it increases balance-sheet concentration risk when funded without operational self-sufficiency.

Two: Out-licensing functions as a liquidity valve, but negotiating leverage dictates the price. For a China-based biopharmaceutical firm navigating domestic single-payer price controls, selling ex-China commercial rights represents a high-return strategy for pipeline assets. RemeGen executed four major out-licensing transactions across five years, each providing cash inflows at critical operating junctures.

Yet the sequence of transaction terms underscores how financial condition governs deal execution. In August 2021, operating from financial strength following its Hong Kong listing, RemeGen secured US$200 million in upfront cash from Seagen. In June 2025, holding less than RMB 1 billion in cash following an uncompleted A-share private placement, the company accepted US$45 million in upfront cash alongside equity warrants for the international rights to telitacicept. By January 2026, with liquidity replenished by intermediate licensing deals and high demand for bispecific oncology targets, RemeGen commanded US$650 million upfront from AbbVie. Evaluating an out-licensing strategy requires distinguishing whether management transacts opportunistically from liquidity strength or reactively to extend cash runway.

Three: Regulatory approval is not a moat, and upfront payments do not guarantee global commercialization. Disitamab vedotin achieved first-in-class domestic approval in China, generated positive first-line Phase 3 survival data in urothelial cancer, and attracted a major international development partner. None of these achievements prevented global development from halting due to portfolio overlap at Pfizer, nor did they prevent domestic growth from slowing from 36% in 2024 to 22.45% in 2025 as rival domestic ADCs entered the market. First-mover advantages in drug discovery are perishable; durable enterprise value depends on cost structure, field execution, and institutional distribution.

Four: Reported profits can obscure underlying business economics. RemeGen reported profitable periods in 2025 and the first half of 2026 that did not reflect baseline operational performance. Net profit in 2025 relied primarily on marking up the paper value of equity warrants received from Vor Bio, while first-half 2026 profitability stemmed from recognizing a single upfront licensing payment from AbbVie. Both outcomes followed standard accounting rules, yet neither represented self-sustaining drug sales. Evaluating the core enterprise requires analyzing organic product sales net of commercialization and administrative overhead—a figure that required six years of commercial operations to approach breakeven.

Five: In China's pharmaceutical market, distribution infrastructure is a scarcer asset than individual molecules. The most enduring asset RemeGen built may not be its lead molecules, but its two specialized field forces, each maintaining formulary access across more than 1,000 tertiary hospitals. Establishing that institutional presence required years of capital deployment, yet it creates reusable distribution infrastructure for future pipeline launches. Individual therapeutic candidates risk competitive erosion within years, whereas established hospital listings compound operating leverage over time.

↑ Back to Top

XI. Analysis, Key KPIs, & Bull vs. Bear Verdict

Myth versus reality. Three consensus narratives regarding RemeGen require direct clarification.

The myth that RemeGen reached profitability in 2025. While the company reported a net profit for the year, excluding non-recurring items reveals baseline operating profitability of RMB 68 million on RMB 3.25 billion in revenue—essentially an operational breakeven achieved with the assistance of a 20.85% reduction in research spending.²³ Management's own target for genuine, ex-licensing operational breakeven applies to 2026, not 2025.²¹

The myth that the Pfizer impairment signals clinical failure. The write-down of disitamab vedotin illustrates deal structure dynamics and portfolio overlap rather than a failure of drug science. Clinical results in first-line urothelial cancer were robust. Development was deprioritized because Pfizer owned a competing compound in the same therapeutic indication, and subsequent impairments were driven by commercial projections for that internal asset rather than performance flaws in disitamab vedotin.³⁰

The myth that repeated out-licensing confirms a self-sustaining business model. Recurring licensing transactions demonstrate strong technical discovery capabilities and an effective cash-generation mechanism. While valuable, out-licensing transactions differ fundamentally from an operating business that consistently compounds retained earnings from drug sales—a distinction central to the investment thesis.

The three KPIs that matter.

First: domestic product sales growth, tracked separately for each asset. Total revenue remains distorted by upfront licensing payments, making organic product sales the critical baseline. The company's two core commercial engines are diverging: the autoimmune franchise expanded at roughly twice the rate of oncology in 2025, while the first half of 2026 showed further deceleration in combined product sales growth.²¹³ Whether new indication launches for telitacicept reaccelerate aggregate volume, and whether disitamab vedotin stabilizes against expanding domestic ADC competition, represents the primary operational test.

Second: the selling expense ratio relative to product sales. This metric determines whether RemeGen can achieve operational self-funding. The margin efficiency recorded in the first half of 2026 was notable, but sustaining cost discipline alongside volume growth is the key test.³ Monitoring this ratio alongside research outlays clarifies whether margin gains reflect structural operating leverage or temporary reductions in pipeline investment.

Third: the ex-China regulatory and milestone track—specifically the Vor Bio global gMG Phase 3 readout expected in the first half of 2027. Valuations assigned to telitacicept's international market potential depend heavily on that trial result and the accompanying Sjögren's disease program.²⁰ Disclosed cash milestone receipts from AbbVie and Vor Bio represent the secondary indicator, validating whether headline contract figures translate into collected funds.

The bear case. RemeGen distributes products within a domestic market governed by a single-payer monopsony that negotiates reimbursement pricing annually without competing bidders. Commercial distribution costs absorb nearly half of organic product revenue. The oncology franchise faces intensifying domestic competition, with annual growth rates slowing. Outside Greater China, commercial rights to its lead autoimmune asset were licensed to a micro-cap partner in exchange for equity warrants, while rights to its ophthalmology candidate—both domestically and across Southeast Asia—were assigned to a Japanese licensee. Reported profits remain heavily influenced by non-operating accounting items. Research expenditures declined across consecutive periods despite leadership asserting that discovery drives long-term value, and the broader pipeline exhibits a low historical conversion rate from early candidate to approved revenue, formalized in a half-billion-renminbi write-off. Furthermore, three senior executives departed during periods of financial strain, while the structural risk that disrupted the Seagen partnership—a licensee's competing internal pipeline—remains unmitigated across subsequent licensing agreements.

The bull case. Conversely, a regional biopharmaceutical firm established without venture backing successfully developed three first-in-class biologics, securing regulatory approvals across five indications for its two commercialized assets. The company manufactures these biologics in-house at gross margins in the mid-80s. Operating without distribution partners, it constructed two specialized field forces achieving hospital formulary access across more than 1,000 institutions each—an operational asset built over six years that competitors cannot easily duplicate. Its autoimmune franchise addresses chronic conditions with high patient persistence and a domestic target population in the millions, securing two new indication approvals in June 2026 while limiting price reductions to single digits during recent reimbursement renewals. On three occasions over five years, major international pharmaceutical acquirers committed hundreds of millions of dollars to license candidates from its discovery platform. Following the AbbVie upfront payment, cash reserves reached approximately RMB 3.84 billion against a clear guidance trajectory toward operational breakeven, placing the balance sheet in its strongest financial position to date.³²¹

Weighing it. The empirical evidence supports a more measured conclusion than either extreme thesis suggests. RemeGen's drug discovery engine is validated, having secured major international licensing payments and published peer-reviewed clinical datasets in leading medical journals. Its domestic commercial enterprise is real—durable within rheumatology and neurology, though contested within oncology. Financially, the historical record refutes claims of disciplined capital allocation, demonstrating instead a pattern of resourceful financing that secured capital at critical junctures, often under constrained bargaining positions.

What remains to be established is whether the financial stabilization observed in 2025 and 2026 marks a structural inflection point or a temporary operational reprieve. Two clear indicators would confirm a sustained turnaround: achieving a full fiscal year of positive operating cash flow excluding licensing income, and delivering a positive global Phase 3 trial readout that establishes telitacicept beyond the domestic market. Conversely, two developments would invalidate the recovery thesis: continued deceleration in product sales below company targets alongside stagnating expense ratios, or a return to equity dilution before existing cash reserves are converted into self-sustaining commercial assets.

For an enterprise defined by a continuous race between laboratory discovery and cash burn, these operational metrics represent the ultimate measure of performance.